Amylin Pharmaceuticals to Webcast Third Quarter Results

Oct 13, 2010, 16:15 ET from Amylin Pharmaceuticals, Inc.

SAN DIEGO, Oct. 13, 2010 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) will webcast its Quarterly Update Conference Call for the third quarter of 2010 on Wednesday, October 20, 2010 at 5:00 p.m. ET/2:00 p.m. PT. Daniel M. Bradbury, Amylin's president and chief executive officer, will lead the call. On the same date post-market, Amylin will release financial results for the third quarter of 2010.  

The call will be webcast live through the "Investors" section of Amylin's corporate Web site and a recording will be made available following the close of the call. To access the webcast, please log on to www.amylin.com approximately fifteen minutes prior to the call to register, download and install any necessary audio software. For those without access to the Internet, the live call may be accessed by phone by calling (800) 857-5738 (U.S./Canada) or (415) 228-4970 (international), participant passcode number 7487145. A replay of the call will also be available by phone beginning approximately two hours after the close of the call and can be accessed at (800) 468-0325 (U.S./Canada) or (402) 998-0109 (international).

About Amylin Pharmaceuticals

Amylin Pharmaceuticals is a biopharmaceutical company dedicated to improving lives of patients through the discovery, development and commercialization of innovative medicines. Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN® (pramlintide acetate) injection and BYETTA® (exenatide) injection. Amylin's research and development activities leverage the Company's expertise in metabolism to develop potential therapies to treat diabetes and obesity. Amylin is headquartered in San Diego, California. Further information on Amylin Pharmaceuticals is available at www.amylin.com.

SOURCE Amylin Pharmaceuticals, Inc.



RELATED LINKS

http://www.amylin.com